Table 1 of
Hildebrand, Mol Vis 2014; 20:1749-1757. Table 1 of
Hildebrand, Mol Vis 2014; 20:1749-1757.
Table 1. Groups and treatments.
| Group | Recipient age in weeks | Treatment | n | Survival until POD29, n(%) |
|---|---|---|---|---|
| allogenic | 3 | none | 23 | 0 (0) |
| allogenic | 3 | CD4+CD25+ i.v. | 4 | 0 (0) |
| allogenic | 3 | CD4+CD25+ s.c. | 6 | 4 (66.7) |
| allogenic | 3 | CD4+ CD25- s.c. | 4 | 1 (25) |
| allogenic | 10 | none | 4 | 0 (0) |
| allogenic | 10 | CD4+CD25+ s.c. | 6 | 2 (33.3) |
| allogenic | 10 | CD4+ CD25- s.c. | 6 | 0 (0) |
| syngenic | 3 | none | 8 | 8 (100) |
| syngenic | 10 | none | 4 | 4 (100) |